Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease.
Iwata
Shigeru
S
Saito
Kazuyoshi
K
Yamaoka
Kunihiro
K
Tsujimura
Shizuyo
S
Nawata
Masao
M
Suzuki
Katsunori
K
Tanaka
Yoshiya
Y
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001528:Behcet Syndrome / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D000069285:Infliximab; D007410:Intestinal Diseases / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D055815:Young Adult
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab